

Zealand Pharma, Uniquist collaborate for gastrointestinal drugs

21 February 2018 | News

Zealand Pharma will use the proprietary peptide technology and world-leading expertise of UQ's Institute for Molecular Bioscience



The commercialisation company of The University of Queensland (UQ), Australia announced collaboration with Zealand Pharma to identify novel peptide therapeutics inspired by venoms as potential new treatments for gastrointestinal diseases.

Zealand Pharma will use the proprietary peptide technology and world-leading expertise of UQ's Institute for Molecular Bioscience (IMB), as well as expertise from Flinders University in South Australia.

Zealand and the university researchers will work together to characterise venom-derived peptides that act against undisclosed targets to identify novel drug candidates for further development by Zealand.

Zealand has a strong track record and world-leading capabilities in the discovery and development of peptides for therapeutic use in gastrointestinal and metabolic diseases.